{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:40:06Z","timestamp":1744137606245,"version":"3.40.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"DOI":"10.7759\/cureus.81903","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:58:40Z","timestamp":1744135120000},"source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Evaluation of the Efficacy of Combined Antiviral Therapy Versus Monotherapy in High-Risk Hospitalized COVID-19 Patients"],"prefix":"10.7759","author":[{"given":"Hind Khalid","family":"Goresh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha K","family":"Almutiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer O","family":"Hadari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghdaa M","family":"Alzain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shatha K","family":"Altewajri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Coronaviruses (COVID-19). (2024). Accessed. 02\/10\/2024: https:\/\/www.nfid.org\/infectious-disease\/coronaviruses\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119789741.ch1","article-title":"COVID-19: epidemiology","author":"Quiroz P","year":"2022","unstructured":"Quiroz P, Rutherford GW, Dube MP. COVID-19: epidemiology. Coronavirus Disease 2019 (COVID\u201019): A Clinical Guide. Gholamrezanezhad A, Dube MP (ed): Wiley, 2022. 1-21. 10.1002\/9781119789741.ch1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li G","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023, 22:449-75. 10.1038\/s41573-023-00672-y","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.26719\/emhj.21.048","article-title":"COVID-19 in Saudi Arabia: the national health response","volume":"27","author":"Khan A","year":"2021","unstructured":"Khan A, Alsofayan Y, Alahmari A, et al.. COVID-19 in Saudi Arabia: the national health response. East Mediterr Health J. 2021, 27:1114-24. 10.26719\/emhj.21.048","journal-title":"East Mediterr Health J"},{"key":"ref5","unstructured":"Saudi MoH protocol for patients suspected of\/confirmed with COVID-19. (2023). Accessed. 02\/10\/2024: https:\/\/www.moh.gov.sa\/en\/Ministry\/MediaCenter\/Publications\/Documents\/MOH-therapeutic-protocol-for-COVID-19.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson BN","year":"2020","unstructured":"Williamson BN, Feldmann F, Schwarz B, et al.. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020, 585:273-6. 10.1038\/s41586-020-2423-5","journal-title":"Nature"},{"key":"ref7","article-title":"","author":"Whalen K","year":"2022","unstructured":"Whalen K. Lippincott Illustrated Reviews: Pharmacology. Wolters Kluwer, 2022. https:\/\/shop.lww.com\/Lippincott-Illustrated-Reviews--Pharmacology\/p\/9781975170554?srsltid=AfmBOoputVZXebb1ZxMff2yFh7A...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1920900","article-title":"Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis","volume":"37","author":"Alamer A","year":"2021","unstructured":"Alamer A, Alrashed AA, Alfaifi M, et al.. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021, 37:1085-97. 10.1080\/03007995.2021.1920900","journal-title":"Curr Med Res Opin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2021.0489.R1.13082021","article-title":"Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study","volume":"140","author":"Erg\u00fcr F\u00d6","year":"2022","unstructured":"Erg\u00fcr F\u00d6, Y\u0131ld\u0131z M, \u015eener MU, Kavurgac\u0131 S, Ozturk A. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study. Sao Paulo Med J. 2022, 140:372-7. 10.1590\/1516-3180.2021.0489.R1.13082021","journal-title":"Sao Paulo Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18030847","article-title":"Assessment of the quality of life during COVID-19 pandemic: a cross-sectional survey from the Kingdom of Saudi Arabia","volume":"18","author":"Algahtani FD","year":"2021","unstructured":"Algahtani FD, Hassan SU, Alsaif B, Zrieq R. Assessment of the quality of life during COVID-19 pandemic: a cross-sectional survey from the Kingdom of Saudi Arabia. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18030847","journal-title":"Int J Environ Res Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020060875","article-title":"Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study","volume":"32","author":"De Meester J","year":"2021","unstructured":"De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2021, 32:385-96. 10.1681\/ASN.2020060875","journal-title":"J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou F","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4551132","article-title":"Factors associated with poor treatment outcome among hospitalized COVID-19 patients in south central, Ethiopia","volume":"2022","author":"Kaso AW","year":"2022","unstructured":"Kaso AW, Hareru HE, Kaso T, Agero G. Factors associated with poor treatment outcome among hospitalized COVID-19 patients in south central, Ethiopia. Biomed Res Int. 2022, 2022:4551132. 10.1155\/2022\/4551132","journal-title":"Biomed Res Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil AC","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al.. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021, 384:795-807. 10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202101_24427","article-title":"Safety and efficacy of oral lopinavir\/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis","volume":"25","author":"Lu JM","year":"2021","unstructured":"Lu JM, Zhou AF, Zhang XB, et al.. Safety and efficacy of oral lopinavir\/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis. Eur Rev Med Pharmacol Sci. 2021, 25:549-55. 10.26355\/eurrev_202101_24427","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska M","year":"2023","unstructured":"Mikulska M, Sepulcri C, Dentone C, et al.. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023, 77:280-6. 10.1093\/cid\/ciad181","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai Q","year":"2020","unstructured":"Cai Q, Yang M, Liu D, et al.. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020, 6:1192-8. 10.1016\/j.eng.2020.03.007","journal-title":"Engineering (Beijing)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.04.001","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial","volume":"1","author":"Li Y","year":"2020","unstructured":"Li Y, Xie Z, Lin W, et al.. Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020, 1:105-13.e4. 10.1016\/j.medj.2020.04.001","journal-title":"Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09741-5","article-title":"Efficacy and safety of the sofosbuvir\/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19","volume":"12","author":"Messina V","year":"2022","unstructured":"Messina V, Nevola R, Izzi A, et al.. Efficacy and safety of the sofosbuvir\/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Sci Rep. 2022, 12:5771. 10.1038\/s41598-022-09741-5","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121430-20201019-00679","article-title":"Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019 [Article in Chinese]","volume":"32","author":"Gao X","year":"2020","unstructured":"Gao X, Ma C, Ma Y, et al.. Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019 [Article in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020, 32:1423-7. 10.3760\/cma.j.cn121430-20201019-00679","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047561","article-title":"Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: a retrospective cohort study","volume":"11","author":"Basu A","year":"2021","unstructured":"Basu A, Agwu JC, Barlow N, Lee B. Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: a retrospective cohort study. BMJ Open. 2021, 11:e047561. 10.1136\/bmjopen-2020-047561","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89548-y","article-title":"Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study","volume":"11","author":"Song J","year":"2021","unstructured":"Song J, Park DW, Cha JH, Seok H, Kim JY, Park J, Cho H. Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study. Sci Rep. 2021, 11:10066. 10.1038\/s41598-021-89548-y","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20203455","article-title":"Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study","volume":"40","author":"Boari GE","year":"2020","unstructured":"Boari GE, Chiarini G, Bonetti S, et al.. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. Biosci Rep. 2020, 40:10.1042\/BSR20203455","journal-title":"Biosci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.08.011","article-title":"Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study","volume":"26","author":"Nachtigall I","year":"2020","unstructured":"Nachtigall I, Lenga P, J\u00f3\u017awiak K, et al.. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect. 2020, 26:1663-9. 10.1016\/j.cmi.2020.08.011","journal-title":"Clin Microbiol Infect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.019","article-title":"Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up","volume":"80","author":"Wang L","year":"2020","unstructured":"Wang L, He W, Yu X, et al.. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020, 80:639-45. 10.1016\/j.jinf.2020.03.019","journal-title":"J Infect"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121411","article-title":"Evaluation of treatment outcome for pneumonia among pre-vaccinated Covid-19 patients with\/without comorbidity in a public hospital in Bengkulu, Indonesia","volume":"9","author":"Ramatillah DL","year":"2021","unstructured":"Ramatillah DL, Gan SH, Sulaiman SA, et al.. Evaluation of treatment outcome for pneumonia among pre-vaccinated Covid-19 patients with\/without comorbidity in a public hospital in Bengkulu, Indonesia. Vaccines (Basel). 2021, 9:1411. 10.3390\/vaccines9121411","journal-title":"Vaccines (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.02.007","article-title":"Hospitalized patients with breakthrough COVID-19: clinical features and poor outcome predictors","volume":"118","author":"Moreno-Perez O","year":"2022","unstructured":"Moreno-Perez O, Ribes I, Boix V, et al.. Hospitalized patients with breakthrough COVID-19: clinical features and poor outcome predictors. Int J Infect Dis. 2022, 118:89-94. 10.1016\/j.ijid.2022.02.007","journal-title":"Int J Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01684-9","article-title":"COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences","volume":"50","author":"Tabernero E","year":"2022","unstructured":"Tabernero E, Ruiz LA, Espa\u00f1a PP, et al.. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. Infection. 2022, 50:179-89. 10.1007\/s15010-021-01684-9","journal-title":"Infection"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056464","article-title":"Clinicodemographic profile and predictors of poor outcome in hospitalised COVID-19 patients: a single-centre, retrospective cohort study from India","volume":"12","author":"Tiwari L","year":"2022","unstructured":"Tiwari L, Gupta P, N Y, et al.. Clinicodemographic profile and predictors of poor outcome in hospitalised COVID-19 patients: a single-centre, retrospective cohort study from India. BMJ Open. 2022, 12:e056464. 10.1136\/bmjopen-2021-056464","journal-title":"BMJ Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357675-retrospective-evaluation-of-the-efficacy-of-combined-antiviral-therapy-versus-monotherapy-in-high-risk-hospitalized-covid-19-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:58:44Z","timestamp":1744135124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357675-retrospective-evaluation-of-the-efficacy-of-combined-antiviral-therapy-versus-monotherapy-in-high-risk-hospitalized-covid-19-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.81903","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}